Day: June 1, 2020

AUSTIN, Texas, June 01, 2020 (GLOBE NEWSWIRE) — Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden diseases, today announced it will provide a corporate overview at BIO Digital being held virtually June 8-12, 2020.Presentation DetailsDate: June 8-12, 2020Presenter: Anthony G. Quinn, M.B. Ch.B., Ph.D., Aeglea’s president and chief executive officerLocation: https://www.bio.org/events/bio-digitalThe presentation will be available for download on the Presentations & Events section of the Company’s website and also will be available on-demand to registered participants of BIO Digital at https://www.bio.org/events/bio-digital/sessions/620997.About Aeglea BioTherapeuticsAeglea BioTherapeutics...

REDWOOD CITY, Calif. and JUPITER, Fla., June 01, 2020 (GLOBE NEWSWIRE) — Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company and developer of high-performance enzymes, and Alphazyme LLC, an emerging leader in the development and manufacture of nucleic acid metabolizing enzymes, announce a Co-Marketing & Enzyme Supply Collaboration Agreement for the production and co-marketing of enzymes for life science applications.The agreement covers the launch of three enzymes to prospective customers over the second and third quarters of 2020. The first enzyme is a high-fidelity DNA polymerase, following up on Codexis’ previously announced high performance DNA ligase, which was exclusively licensed to Roche in late 2019. The Codexis-developed DNA polymerase has been engineered to deliver high fidelity and uniformity of...

Regulated informationJune 1, 2020Breda, the Netherlands / Ghent, Belgium — argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, announced today the closing of its previously announced global offering of an aggregate of 4,207,292 ordinary shares (including ordinary shares represented by American Depositary Shares (ADSs)), which includes the full exercise of the underwriters’ option to purchase 548,777 additional ADSs. The gross proceeds from the global offering were approximately $862.5 million (approximately €784.7 million).J.P. Morgan, Cowen and BofA Securities acted as joint bookrunning managers for the offering. Stifel, JMP Securities, Wedbush PacGrow, Nomura and Kempen & Co...

CAMBRIDGE, Mass., June 01, 2020 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, announced today that it has commenced an underwritten public offering of $75 million of shares of its common stock. Intellia also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the public offering. All of the shares in the proposed offering are to be sold by Intellia.Goldman Sachs & Co. LLC, Jefferies and SVB Leerink are acting as joint book-running managers for the proposed offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may...

Press release – No. 06 / 2020Zealand Pharma to attend Jefferies and Goldman Sachs Virtual Healthcare ConferencesCopenhagen, June 1, 2020 – Zealand Pharma A/S (Nasdaq: ZEAL), a biotechnology company changing lives with innovative peptide-based medicines, will participate in two upcoming investor conferences.On June 4, 2020, Chief Executive Officer Emmanuel Dulac and Chief Financial Officer Matt Dallas will participate in the Jefferies 2020 Virtual Healthcare Conference.  In addition to meeting with individual investors, both executives are scheduled to participate in a “fireside chat” with a research analyst on Thursday, June 4, 2020 from 11:00 to 11:25 AM Eastern. The presentation can be accessed at http://wsw.com/webcast/jeff126/zeal/. A replay of this presentation will be accessible via the same link, and will be available after the...

VANCOUVER, British Columbia, June 01, 2020 (GLOBE NEWSWIRE) — Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, today reported financial results for the three months ended March 31, 2020 (“First Quarter 2020”) and associated Company developments. Unless otherwise noted, all figures are in Canadian currency.“Today the Company reported record quarterly revenues of $579,450 for Q1 2020, a 76% increase in revenues compared to Q1 2019,” said Doug Janzen, Chairman and CEO of Aequus. “We ended 2019 with strong sales momentum and are pleased to report a record quarter in Q1 2020, almost doubling revenues over the same period 12 months ago. The revenue growth was primarily due to increases...

Hexatronic Group AB (publ) 556168-6360Pressmeddelande 1 juni 2020Hexatronic tecknar avtal om förvärv av det brittiska fiberoptikbolaget Tech OpticsHexatronic Group AB (publ) (”Hexatronic”) har den 1 juni ingått avtal om förvärv av samtliga aktier i det brittiska fiberoptikbolaget Tech Optics Ltd. (“Tech Optics”).Tech Optics är en leverantör och tillverkare av fiberoptiska komponenter som grundades 1988. Bolaget specialiserar sig på fiberoptiska komponenter för extrema miljöer som till exempel försvar, flygindustri och olja och gasindustri. Tech Optics är en godkänd leverantör till den brittiska försvarsindustrin och tillhandahåller flera ledande bolag globalt med en stor variation av fiberoptiska kommunikationsprodukter, skräddarsydda fiberoptiska kablar och fiberoptisk expertis.Förvärvet har ingen betydande påverkan på Hexatronics lönsamhet.“Tech...

Hexatronic Group AB (publ) 556168-6360Press Release June 1, 2020Hexatronic to acquire UK-based fiber optic company Tech Optics Ltd.Hexatronic Group AB (publ) (”Hexatronic”) has on June 1 entered into an agreement to acquire all shares in the UK-based fiber optic company Tech Optics Limited (“Tech Optics”).Tech Optics is a fiber optic products supplier and cable assembly manufacturer, established since 1988. The company specialises in applications within harsh environments, for example defence, aerospace, oil and gas industry. Tech Optics is an approved supplier to the UK defence industry and provides many leading companies worldwide with an extensive range of fiber optic communications products, customised fiber optic cable assemblies and fiber optic expertise.The acquisition has no significant impact on Hexatronic’s earnings.“Tech Optics...

VANCOUVER, British Columbia, June 01, 2020 (GLOBE NEWSWIRE) — Eastern Zinc Corp. (“Eastern Zinc” or the “Company”) (CSE:EZNC | OTC:ETZCF) is pleased to announce that it has entered into a definitive purchase agreement with Platina Resources Limited (“Platina”) (ASX: PGM), dated June 1, 2020, for the acquisition of a 100% undivided ownership interest in the Skaergaard precious metals project (the “Skaergaard Project” or the “Project”) located on the East Coast of Greenland.The Skaergaard ProjectThe Skaergaard Project is comprised of two exploration licences and contains a significant historical resource estimate of gold and platinum group metals (PGMs) dominated by palladium, importantly, outside of the major PGM producing areas of South Africa and Russia. This historical estimate is predominantly in the Inferred resource...

CALGARY, Alberta, June 01, 2020 (GLOBE NEWSWIRE) — Champion Bear Resources Ltd. (TSXV: CBA-V) (“Champion Bear” or the “Company“) announces that further to its April 29, 2020 press release due to circumstances created by the COVID-19 pandemic, it is continuing to rely on Blanket Order 51-517 – Temporary Exemption from Certain Corporate Finance Requirements of the Alberta Securities Commission (“ASC 51-517“) (and similar exemptions provided by the British Columbia and Ontario Securities Commissions), to postpone the filing of the certain continuous disclosure documents required by National Instrument 51-102 – Continuous Disclosure Documents (“NI 51-102“).  Pursuant to ASC 51-517 during the period from March 23, 2020 to June 1, 2020, a person or company required to make certain filings...